A novel device to capture circulating tumor cells: Quantification and molecular analysis in lung cancer patients

Cheng, Yuxin; Shen, Jie; Yuan, Ling; Yang, Yan; Shen, Xizhong; Hu, Qian; Yu, Lan; Li, Rutian; Lv, Xin; Yan, Tingting; Li, Yan; Wang, Lifeng; Liu, Baorui

doi:10.1177/0885328220914408

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The herringbone microfluidic chip has been optimized by theoretical study such as COMSOL physics simulation in some other research and mainly applied in circulating cancer cells capture. [42][43][44][45][46] With sEVs emerging as biomarker in liquid biopsy, the herringbone microfluidic chip gradually applied for sub-group sEV capture. [43,47,48] And in this work, we mainly focus on new functionalization on interface of the chip and special application in pan-cancer screening.…”

Section: Fabrication Of the Hb Ev-chip And Strategy For Ps + Sev Isol...mentioning

confidence: 99%

Tim4‐Functionalized ^HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Yang

Tong

Zhang

et al. 2021

Adv Materials Technologies

Self Cite

View full text Add to dashboard Cite

immune cells, histiocytes, and tumor cells) through the endolysosomal pathway. First, endocytosis of the cell membrane leads to formation of early endosomes, which fuse to form multivesicular bodies; then, the endocytosis of multivesicular bodies form exosomes secreted into extracellular space. [2] It has been reported that exosomes level in plasma of tumor patients is generally higher than that of healthy individuals and is closely associated with the type and progression of tumor. [3][4][5][6] Further studies have shown that exosomes carry multiple biological molecules, such as lipids, proteins and RNAs, which mirror the characteristics of source cells. [7] Therefore, tumor-derived exosomes are being recognized as potential cancer monitors in circulating liquids. As consensus on specific extracellular vesicle markers have not been reached yet, we took sEVs as a replacement term of exosomes in the follow-up paragraphs, in accordance with the MISEV2018 recommendations. [8] Pan-cancer screening is an approach to achieving universe cancer detection simultaneously from a single test, driven by biology and epidemiology. [9] As it would early detect the multiple cancer with pre-symptomy, pan-cancer screening contributes to decreasing the mortality rate of cancers, especially for the cancers without standard of care (SOC) screening method. And compared with a particular cancer type detection, it could increase the diagnostic efficiency for tumors derived from diverse organs. [10] But in liquid biopsy, sEVs are generally emerging as a diagnostics test for a particular cancer type and few applied in multiple cancer screening, which mainly focus on proteins and RNAs carried by sEVs. [11][12][13][14][15][16] Hence, there remains to be researched on lipids carried by sEVs in pan-cancer screening.Phosphatidylserine (PS) is an anionic lipid that is present in intracellular membranes in normal cells. However, in the tumor microenvironment, PS is affected by the influx of calcium ions, [17] flippase inactivation, [18] oxidative stress, [19] and radiochemotherapy, [20] resulting in abnormal flipping of PS to the outside of tumor cell membranes, such as in the non-small cell lung cancer cell lines A549 and H1975, pancreatic cancer cell line MIA PaCa-2, colorectal cancer cell line HT-29, and breast Thanks to containing tumor-related molecules, small extracellular vesicles (sEVs) are emerging as biomarkers in tumor liquid biopsy and commonly employed to diagnose a specific cancer. However, a pan-cancer screening method for pre-symptomatic patients is crucial to achieving the early cancer detection. Herein, a lipid-protein capture system on herringbone (HB) microfluidic chip ( HB EV-Chips) to isolate multiple tumor-derived sEVs is constructed. Phosphatidylserine (PS) is abnormally surface-supposed on tumor-derived sEVs and binds T-cell immunoglobulin domain and mucin domain-containing protein 4 (Tim4) in calcium-dependent manner. PS + sEVs isolated by the HB EV-Chips is perform on liquid chromatography electrospray ionization tandem...

show abstract

Section: Fabrication Of the Hb Ev-chip And Strategy For Ps + Sev Isol...mentioning

confidence: 99%

Tim4‐Functionalized ^HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Yang

Tong

Zhang

et al. 2021

Adv Materials Technologies

Self Cite

View full text Add to dashboard Cite

show abstract

“…In literature, different system designed for CTCs analysis have been described with different costs and many advantages compared to tissue biopsy. A new micro-filter system to detect the CTCs with low costs was described by Cheng et al [ 12 ], whereas Maheswaran et al [ 13 ] demonstrated the ability to identify epidermal growth factor receptor mutations from CTCs isolated with a microchip device [ 14 ]. Actually, a recent study conducted at the MD Anderson Cancer Center (Houston, Texas), concluded that the NGS analysis on the tumor genome obtained from LB can completely replace tissue biopsy with the advantage of a reduced turnaround time (TAT).…”

Section: Diagnostic and Prognostic Value Of Circulating Biomarkersmentioning

confidence: 99%

Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers

Vicidomini

Cascone

Carlucci

et al. 2020

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small cell lung cancer (NSCLC) is strictly dependent on feasibility of a complete surgical resection of the tumor at diagnosis. Since surgery is indicated only in early stages tumors, it is necessary to anticipate the timing of diagnosis in clinical practice. In the diagnostic and therapeutic pathway for NSCLC, sampling of neoplastic tissue is usually obtained using invasive methods that are not free from disadvantages and complications. A valid alternative to the standard biopsy is the liquid biopsy (LB), that is, the analysis of samples from peripheral blood, urine, and other biological fluids, with a simple and non-invasive collection. In particular, it is possible to detect in the blood different tumor derivatives, such as cell-free DNA (cfDNA) with its subtype circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), and circulating tumor cells (CTCs). Plasma-based testing seems to have several advantages over tumor tissue biopsy; firstly, it reduces medical costs, risk of complications related to invasive procedures, and turnaround times; moreover, the analysis of genes alteration, such as EGFR, ALK, ROS1, and BRAF is faster and safer with this method, compared to tissue biopsy. Despite all these advantages, the evidences in literatures indicate that assays performed on liquid biopsies have a low sensitivity, making them unsuitable for screening in lung cancer at the current state. This is caused by lack of standardization in sampling and preparation of specimen and by the low concentration of biomarkers in the bloodstream. Instead, routinely use of LB should be preferred in revaluation of patients with advanced NSCLC resistant to chemotherapy, due to onset of new mutations.

show abstract

A novel device to capture circulating tumor cells: Quantification and molecular analysis in lung cancer patients

Cited by 2 publications

References 34 publications

Tim4‐Functionalized ^HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Tim4‐Functionalized ^HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers

Contact Info

Product

Resources

About

A novel device to capture circulating tumor cells: Quantification and molecular analysis in lung cancer patients

Cited by 2 publications

References 34 publications

Tim4‐Functionalized HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Tim4‐Functionalized HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers

Contact Info

Product

Resources

About

Tim4‐Functionalized ^HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening

Tim4‐Functionalized ^HBEV‐Chip by Isolating Plasma‐Derived Phosphatidylserine‐Positive Small Extracellular Vesicles for Pan‐Cancer Screening